NCT01375569: TRC105 for Liver Cancer That Has Not Responded to Sorafenib |
|
|
| Completed | 2 | 11 | US | TRC105 | National Cancer Institute (NCI) | Hepatocellular Carcinoma, Hepatocellular Cancer, Carcinoma, Hepatocellular | 02/14 | 12/15 | | |
NCT01727089: Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer |
|
|
| Completed | 2 | 59 | US, RoW | Anti-Endoglin Chimeric Monoclonal Antibody TRC105, TRC105, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pharmacological Study | National Cancer Institute (NCI) | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma | 08/17 | 08/17 | | |
| Completed | 1/2 | 27 | US | TRC 105, Sorafenib, Nexavar | National Cancer Institute (NCI) | Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, Carcinoma, Hepatocellular, Liver Neoplasms, Experimental | 06/16 | 06/17 | | |
